158
HR 2264 PP
report concerning the study to the Committee on
Labor and Human Resources and the Committee on
Appropriations of the Senate, and the Committee on
Commerce and the Committee on Appropriations of
the House of Representatives.
(2) REQUIREMENT.—The report under para-
graph (1) shall set forth the findings, conclusions, and
recommendations of the Institute of Medicine for im-
provements in the National Institutes of Health re-
search funding policies and processes and for any
necessary congressional action.
(d) FUNDING.—Of the amount appropriated in this
title for the National Institutes of Health, $300,000 shall
be made available for the study and report under this sec-
tion.
PARKINSON’S DISEASE RESEARCH.
SEC. 212. (a) SHORT TITLE.—This section may be
cited as the ‘‘Morris K. Udall Parkinson’s Research Act of
1997’’.
(b) FINDING AND PURPOSE.—
(1) FINDING.—Congress finds that to take full
advantage of the tremendous potential for finding a
cure or effective treatment, the Federal investment in
Parkinson’s must be expanded, as well as the coordi-
nation strengthened among the National Institutes of
Health research institutes.
159
HR 2264 PP
(2) PURPOSE.—It is the purpose of this section
to provide for the expansion and coordination of re-
search regarding Parkinson’s, and to improve care
and assistance for afflicted individuals and their fam-
ily caregivers.
(c) PARKINSON’S RESEARCH.—Part B of title IV of
the Public Health Service Act (42 U.S.C. 284 et seq.) is
amended by adding at the end the following:
‘‘PARKINSON’S DISEASE
‘‘SEC. 409B. (a) IN GENERAL.—The Director of NIH
shall establish a program for the conduct and support of
research and training with respect to Parkinson’s disease
(subject to the extent of amounts appropriated under sub-
section (e)).
‘‘(b) INTER-INSTITUTE COORDINATION.—
‘‘(1) IN GENERAL.—The Director of NIH shall
provide for the coordination of the program estab-
lished under subsection (a) among all of the national
research institutes conducting Parkinson’s research.
‘‘(2) CONFERENCE.—Coordination under para-
graph (1) shall include the convening of a research
planning conference not less frequently than once
every 2 years. Each such conference shall prepare and
submit to the Committee on Appropriations and the
Committee on Labor and Human Resources of the
Senate and the Committee on Appropriations and the
160
HR 2264 PP
Committee on Commerce of the House of Representa-
tives a report concerning the conference.
‘‘(c) MORRIS K. UDALL RESEARCH CENTERS.—
‘‘(1) IN GENERAL.—The Director of NIH shall
award Core Center Grants to encourage the develop-
ment of innovative multidisciplinary research and
provide training concerning Parkinson’s. The Direc-
tor shall award not more than 10 Core Center Grants
and designate each center funded under such grants
as a Morris K. Udall Center for Research on Parkin-
son’s Disease.
‘‘(2) REQUIREMENTS.—
‘‘(A) IN GENERAL.—With respect to Parkin-
son’s, each center assisted under this subsection
shall—
‘‘(i) use the facilities of a single insti-
tution or a consortium of cooperating insti-
tutions, and meet such qualifications as
may be prescribed by the Director of the
NIH; and
‘‘(ii) conduct basic and clinical re-
search.
‘‘(B) 
DISCRETIONARY
REQUIREMENTS.—
With respect to Parkinson’s, each center assisted
under this subsection may—
161
HR 2264 PP
‘‘(i) conduct training programs for sci-
entists and health professionals;
‘‘(ii) conduct programs to provide in-
formation and continuing education to
health professionals;
‘‘(iii) conduct programs for the dis-
semination of information to the public;
‘‘(iv) separately or in collaboration
with other centers, establish a nationwide
data system derived from patient popu-
lations with Parkinson’s, and where pos-
sible, comparing relevant data involving
general populations;
‘‘(v) separately or in collaboration
with other centers, establish a Parkinson’s
Disease Information Clearinghouse to facili-
tate and enhance knowledge and under-
standing of Parkinson’s disease; and
‘‘(vi) separately or in collaboration
with other centers, establish a national edu-
cation program that fosters a national focus
on Parkinson’s and the care of those with
Parkinson’s.
‘‘(3) STIPENDS
REGARDING
TRAINING
PRO-
GRAMS.—A center may use funds provided under
162
HR 2264 PP
paragraph (1) to provide stipends for scientists and
health professionals enrolled in training programs
under paragraph (2)(B).
‘‘(4) DURATION OF SUPPORT.—Support of a cen-
ter under this subsection may be for a period not ex-
ceeding five years. Such period may be extended by
the Director of NIH for one or more additional peri-
ods of not more than five years if the operations of
such center have been reviewed by an appropriate
technical and scientific peer review group established
by the Director and if such group has recommended
to the Director that such period should be extended.
‘‘(d) MORRIS K. UDALL AWARDS FOR EXCELLENCE IN
PARKINSON’S DISEASE RESEARCH.—The Director of NIH
shall establish a grant program to support investigators
with a proven record of excellence and innovation in Par-
kinson’s research and who demonstrate potential for signifi-
cant future breakthroughs in the understanding of the
pathogensis, diagnosis, and treatment of Parkinson’s.
Grants under this subsection shall be available for a period
of not to exceed 5 years.
‘‘(e) AUTHORIZATION OF APPROPRIATIONS.—For the
purpose of carrying out this section and section 301 and
title IV of the Public Health Service Act with respect to
direct Parkinson’s disease research, there are authorized to
163
HR 2264 PP
be appropriated a total of $100,000,000 for fiscal year 1998,
and such sums as may be necessary for each of the fiscal
years 1999 and 2000.’’.
COMPREHENSIVE FETAL ALCOHOL SYNDROME PREVENTION
SEC. 213. (a) SHORT TITLE.—This section may be
cited as the ‘‘Comprehensive Fetal Alcohol Syndrome Pre-
vention Act’’.
(b) FINDINGS.—Congress finds that—
(1) Fetal Alcohol Syndrome is the leading known
cause of mental retardation, and it is 100 percent
preventable;
(2) each year, up to 12,000 infants are born in
the United States with Fetal Alcohol Syndrome, suf-
fering irreversible physical and mental damage;
(3) thousands more infants are born each year
with Fetal Alcohol Effects, which are lesser, though
still serious, alcohol-related birth defects;
(4) children of women who use alcohol while
pregnant have a significantly higher infant mortality
rate (13.3 per 1000) than children of those women
who do not use alcohol (8.6 per 1000);
(5) Fetal Alcohol Syndrome and Fetal Alcohol
Effects are national problems which can impact any
child, family, or community, but their threat to
American Indians and Alaska Natives is especially
alarming;
164
HR 2264 PP
(6) in some American Indian communities,
where alcohol dependency rates reach 50 percent and
above, the chances of a newborn suffering Fetal Alco-
hol Syndrome or Fetal Alcohol Effects are up to 30
times greater than national averages;
(7) in addition to the immeasurable toll on chil-
dren and their families, Fetal Alcohol Syndrome and
Fetal Alcohol Effects pose extraordinary financial
costs to the Nation, including the costs of health care,
education, foster care, job training, and general sup-
port services for affected individuals;
(8) the total cost to the economy of Fetal Alcohol
Syndrome was approximately $2,700,000,000 in
1995, and over a lifetime, health care costs for one
Fetal Alcohol Syndrome child are estimated to be at
least $1,400,000;
(9) researchers have determined that the possibil-
ity of giving birth to a baby with Fetal Alcohol Syn-
drome or Fetal Alcohol Effects increases in proportion
to the amount and frequency of alcohol consumed by
a pregnant woman, and that stopping alcohol con-
sumption at any point in the pregnancy reduces the
emotional, physical, and mental consequences of alco-
hol exposure to the baby; and
165
HR 2264 PP
(10) though approximately 1 out of every 5 preg-
nant women drink alcohol during their pregnancy, we
know of no safe dose of alcohol during pregnancy, or
of any safe time to drink during pregnancy, thus, it
is in the best interest of the Nation for the Federal
Government to take an active role in encouraging all
women to abstain from alcohol consumption during
pregnancy.
(c) PURPOSE.—It is the purpose of this section to es-
tablish, within the Department of Health and Human Serv-
ices, a comprehensive program to help prevent Fetal Alcohol
Syndrome and Fetal Alcohol Effects nationwide. Such pro-
gram shall—
(1) coordinate, support, and conduct basic and
applied epidemiologic research concerning Fetal Alco-
hol Syndrome and Fetal Alcohol Effects;
(2) coordinate, support, and conduct national,
State, and community-based public awareness, pre-
vention, and education programs on Fetal Alcohol
Syndrome and Fetal Alcohol Effects; and
(3) foster coordination among all Federal agen-
cies that conduct or support Fetal Alcohol Syndrome
and Fetal Alcohol Effects research, programs, and
surveillance and otherwise meet the general needs of
172
HR 2264 PP
‘‘(i) target individuals, families, and
populations identified as being at risk of
acquiring Fetal Alcohol Syndrome and
Fetal Alcohol Effects; and
‘‘(ii) provide health, education, treat-
ment, and social services to infants, chil-
dren, and adults with Fetal Alcohol Syn-
drome and Fetal Alcohol Effects;
‘‘(B) coordinate its efforts with existing De-
partment of Health and Human Services task
forces on substance abuse prevention and mater-
nal and child health; and
‘‘(C) report on a biennial basis to the Sec-
retary and relevant committees of Congress on
the current and planned activities of the partici-
pating agencies, including a proposal for a Fed-
eral Interagency Task Force to include represent-
atives from all relevant agencies and offices with-
in the Department of Health and Human Serv-
ices, the Department of Agriculture, the Depart-
ment of Education, the Department of Defense,
the Department of the Interior, the Department
of Justice, the Department of Veterans Affairs,
the Bureau of Alcohol, Tobacco and Firearms,